8-K: ArriVent BioPharma Changes Auditors, Replacing KPMG with PwC

ArriVent BioPharma has dismissed KPMG as its independent auditor and appointed PricewaterhouseCoopers (PwC) in its place, effective March 11, 2025.

Summary

• ArriVent BioPharma dismissed KPMG as their independent registered public accounting firm on March 11, 2025.
• The dismissal was approved by the Audit Committee and was not due to any disagreements on accounting principles, financial statement disclosure, or auditing scope.
• KPMG's reports on the company's financial statements for 2023 and 2024 did not contain any adverse opinions or disclaimers.
• There were no disagreements between ArriVent and KPMG that would have required reference in KPMG's reports, except for previously reported material weaknesses.
• The material weaknesses related to the review and approval of manual journal entries and the accounting for certain nonroutine transactions, which led to a restatement of the 2022 financial statements.
• These material weaknesses were remediated as of December 31, 2024.
• PricewaterhouseCoopers LLP (PwC) was appointed as the new independent registered public accounting firm for the fiscal year ending December 31, 2025, effective March 11, 2025.
• ArriVent did not consult with PwC on any matters described in Items 304(a)(2)(i) and (ii) of Regulation S-K during the relevant periods.

Sentiment

Score: 7

Explanation: The announcement is fairly neutral. While there was a change in auditors and past material weaknesses, these issues have been addressed. The appointment of PwC is a positive sign.

Positives

• The dismissal of KPMG was not due to disagreements on accounting principles or practices.
• Material weaknesses in internal control over financial reporting, previously reported for 2023, were remediated as of December 31, 2024.

Negatives

• The company had material weaknesses in its internal control over financial reporting in the past, requiring a restatement of the 2022 financial statements.

Risks

• The change in auditors could potentially introduce short-term operational risks as PwC becomes familiar with ArriVent's financial processes and controls.
• Although remediated, the past material weaknesses in internal controls could indicate potential vulnerabilities in the company's financial reporting systems.

Future Outlook

The company will be working with PwC for the fiscal year ending December 31, 2025.

Industry Context

Changes in auditors are not uncommon, but they often prompt scrutiny from investors and analysts, especially when a company has previously reported material weaknesses in internal controls. The appointment of a large, reputable firm like PwC is generally viewed positively, as it can enhance investor confidence in the company's financial reporting.

Comparison to Industry Standards

• Auditor changes are a common occurrence in the biopharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Regeneron use large firms such as PwC, Deloitte, Ernst & Young, and KPMG.
• The selection of PwC aligns ArriVent with industry standards for audit quality and reputation.

Stakeholder Impact

• Shareholders may react to the change in auditors, particularly given the company's history of material weaknesses.
• Employees in the finance and accounting departments will need to work with PwC during the transition.
• The change in auditors is unlikely to have a direct impact on customers or suppliers.

Key Dates